Month: March 2026

Q4 Revenue of $34.9 Million, Net Income of $3.6 Million & Adjusted EBITDA of $7.1 Million, or $8.0 Million Excluding Litigation Expenses LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) — Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”), a global pleasure and leisure company connecting consumers with products, content, and experiences that help them lead happier, more fulfilling lives, today announced financial and operational results for the fourth quarter and full year ended December 31, 2025. Financial Summary($ in millions) Q4 2025 Q4 2024 % ChangeRevenues $34.9 $33.5 4%Operating Expenses $(32.2) $(37.9) (15)%Net Income (Loss) $3.6 $(12.5) 129%Adj. EBITDA (non-GAAP) $7.1 $(0.1) 7200%Fourth Quarter 2025 & Recent Operational Highlights:Licensing revenue remains highly predictable and recurring,...

Net Revenue increased 2.2% to $1,228.3 million for the Full Year 2025 GAAP Net Loss decreased 18.3% to $39.3 million for the Full Year 2025 Adjusted Net Income increased 20.9% to $16.9 million for the Full Year 2025 Adjusted EBITDA increased 6.9% to $ $45.0 million for Full Year 2025 LAS VEGAS, March 16, 2026 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading distributor of international foodservice solutions to Asian restaurants and other businesses across the United States, today announced results for the fourth quarter and year ended December 31, 2025. Full Year and Fourth Quarter 2025 Financial Results(In thousands, except per share amounts)   Year Ended December 31, 2025   Change over Prior Year   Three Months Ended December 31, 2025   Change over Prior Year                 GAAP...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash equivalents, investments, and accounts receivable of $109.4 million, providing cash runway into 2028Kyntra Bio to host conference call and...

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and year ended December 31, 2025. Business Update Discretionary assets under management (“AUM”), which primarily drives the firm’s revenue, decreased 1.2% during the fourth quarter, from $24.3 billion to $24.0 billion. For the year 2025, total discretionary AUM increased by 3%, from $23.3 billion to $24.0 billion, aided by supportive markets and organic net new client accounts. Silvercrest added $124.5 million in organic new client accounts during the fourth quarter, bringing full year 2025 organic new client account flows to $688.3 million. For the full year, organic new client acquisition registered one of the strongest levels over the past...

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. “We are on track to complete this 96-week Phase 3 clinical trial, the largest ever...

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline setting Company is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR altered GBM in Q2 2026 Cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, expected to be sufficient to fund operations into 2H of 2028CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. “We continue to focus...